左西孟旦与多巴酚丁胺治疗失代偿性心力衰竭的临床效果

Clinical effect of levosimendan and dobutamine in the treatment of decompensated heart failure

目的探究左西孟旦与多巴酚丁胺治疗失代偿性心力衰竭的临床效果。方法选取2017年1月至2018年1月我院收治的100例失代偿性心力衰竭患者为研究对象,将其按随机抽签分组方式分为甲组和乙组,每组50例。两组患者均接受常规综合治疗,甲组在此基础上应用左西孟坦,乙组使用多巴酚丁胺。比较两组患者的治疗效果。结果甲组的治疗总有效率显著高于乙组,差异有统计学意义(P<0.05);治疗后,两组患者的HR、PaCO2均显著降低,均显著升高,且甲组优于乙组,差异有统计学意义(P<0.05);甲组的不良反应总发生率明显低于乙组,差异有统计学意义(P<0.05)。结论左西孟旦治疗失代偿性心力衰竭患者的临床效果较好,可更好地控制患者病情,值得临床推广应用。

Objective To explore the clinical effect of levosimendan and dobutamine in the treatment of decompensated heart failure. Methods A total of 100 patients with decompensated heart failure admitted in our hospital from January 2017 to January 2018 were selected as the research objects. The patients were divided into group A and group B according to random lottery grouping, with 50 cases in each group. Both groups received routine comprehensive treatment, the group A was treated with levosimontan and the group B was treated with dobutamine on this basis. The therapeutic effects of the two groups were compared. Results The total effective rate of treatment in the group A was significantly higher than that of the group B, and the difference was statistically significant(P <0.05). After treatment, the HR and PaCO2 in both groups decreased significantly, PaO2 increased significantly, and those in the group A were better than the group B, and the differences were statistically significant(P<0.05). The total incidence of adverse reactions in the group A was significantly lower than that in the group B, and the difference was statistically significant(P<0.05). Conclusion Levosimendan has a good clinical effect in the treatment of decompensated heart failure, which can better control the patient’s condition. It is worthy of clinical popularization and application.